share_log

Guggenheim Initiates Coverage On Immunome With Buy Rating, Announces Price Target of $35

Moomoo 24/7 ·  Apr 15 06:34

Guggenheim analyst Michael Schmidt initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Target of $35.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment